



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



JAMDA

journal homepage: [www.jamda.com](http://www.jamda.com)

## Original Study

# Adverse Events Following One Dose of mRNA COVID-19 Vaccination Among US Nursing Home Residents With and Without a Previous SARS-CoV-2 Infection



Barbara H. Bardenheier PhD, MPH, MA<sup>a,\*</sup>, Stefan Gravenstein MD, MPH<sup>a,b,c</sup>, Carolyn Blackman MD<sup>d</sup>, Roe Gutman PhD<sup>a</sup>, Indra Neil Sarkar PhD, MLIS<sup>b,e</sup>, Richard A. Feifer MD, MPH<sup>d</sup>, Elizabeth M. White APRN, PhD<sup>a</sup>, Kevin McConeghy PharmD<sup>a,c</sup>, Aman Nanda MD<sup>b</sup>, Elliott Bosco PharmD, PhD<sup>a</sup>, Vincent Mor PhD<sup>a</sup>

<sup>a</sup> Brown University School of Public Health, Providence, RI, USA

<sup>b</sup> Warren Alpert Medical School, Brown University, Providence, RI, USA

<sup>c</sup> Providence Veterans Administration Medical Center, Providence, RI, USA

<sup>d</sup> Genesis Physician Services, Kennett Square, PA, USA

<sup>e</sup> Rhode Island Quality Institute, Providence, RI, USA

## A B S T R A C T

## Keywords:

Adverse events after vaccination  
nursing home  
COVID-19 vaccination  
SARS-CoV-2 infection

**Objectives:** To compare rates of adverse events following Coronavirus Disease 2019 (COVID-19) vaccination among nursing home residents with and without previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

**Design:** Prospective cohort.

**Setting and Participants:** A total of 20,918 nursing home residents who received the first dose of messenger RNA COVID-19 vaccine from December 18, 2020, through February 14, 2021, in 284 facilities within Genesis Healthcare, a large nursing home provider spanning 24 US states.

**Methods:** We screened the electronic health record for adverse events, classified by the Brighton Collaboration, occurring within 15 days of a resident's first COVID-19 vaccine dose. All events were confirmed by physician chart review. To obtain risk ratios, multilevel logistic regression model that accounted for clustering (variability) across nursing homes was implemented. To balance the probability of prior SARS-CoV-2 infection (previous positive test or diagnosis by the International Classification of Diseases, 10<sup>th</sup> Revision, Clinical Modification) more than 20 days before vaccination, we used inverse probability weighting. To adjust for multiplicity of adverse events tested, we used a false discovery rate procedure.

**Results:** Statistically significant differences existed between those without ( $n = 13,163$ ) and with previous SARS-CoV-2 infection [symptomatic ( $n = 5617$ ) and asymptomatic ( $n = 2138$ )] for all baseline characteristics assessed. Only 1 adverse event was reported among those with previous SARS-CoV-2 infection (asymptomatic), venous thromboembolism [46.8 per 100,000 residents 95% confidence interval (CI) 8.3–264.5], which was not significantly different from the rate reported for those without previous infection (30.4 per 100,000 95% CI 11.8–78.1). Several other adverse events were observed for those with no previous infection, but were not statistically significantly higher than those reported with previous infection after adjustments for multiple comparisons.

**Conclusions and Implications:** Although reactogenicity increases with preexisting immunity, we did not find that vaccination among those with previous SARS-CoV-2 infection resulted in higher rates of adverse

This research was supported, in part, by a grant from the National Institute on Aging (5U54AG063546–02S5) with supplemental funding from the Centers for Disease Control and Prevention under an interagency agreement. The content and views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government.

SG reports conflicts with vaccine manufacturers related to grants, consulting, and speaking engagements: Sanofi, Seqirus, Pfizer. SG also consults with other pharmaceutical companies such as Longevoron, Janssen, and Merck. SG has grants with Sunovion and Essity. The other authors have no conflicts of interest.

\* Address correspondence to Barbara H. Bardenheier, PhD, Brown University School of Public Health, 121 S. Main Street, Box G-S121–6, Providence, RI 02912, USA.

E-mail address: [Barbara\\_bardenheier@brown.edu](mailto:Barbara_bardenheier@brown.edu) (B.H. Bardenheier).

<https://doi.org/10.1016/j.jamda.2021.08.024>

1525-8610/© 2021 AMDA – The Society for Post-Acute and Long-Term Care Medicine.

events than those without previous infection. This study stresses the importance of monitoring novel vaccines for adverse events in this vulnerable population.

© 2021 AMDA – The Society for Post-Acute and Long-Term Care Medicine.

Little is known about vaccine-related adverse events following Coronavirus Disease 2019 (COVID-19) vaccination among adults with prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. One study found that adults with preexisting natural immunity at time of vaccination more frequently reported side effects such as injection site pain, swelling, and erythema as well as systemic symptoms such as fatigue and headaches, after the first dose of either of the messenger RNA (mRNA) vaccines, compared with those without a previous infection.<sup>1</sup> Given that reactogenicity increases with pre-existing immunity, such side effects are biologically plausible. However, age-related declines in immune system function might suggest that we would not observe the same reactogenicity in the nursing home population. Regardless, no studies have assessed significant adverse events, such as acute myocardial infarction or stroke, following COVID-19 vaccination among older adults with previous SARS-CoV-2 infection.

We observed in a prior study that, compared with unvaccinated nursing home residents, vaccinated residents experienced similar adverse events rates following the first or second COVID-19 mRNA vaccine dose.<sup>2</sup> In that study, residents were classified as vaccinated or unvaccinated, regardless of previous SARS-CoV-2 infection, except those who had tested positive for SARS-CoV-2 within 20 days before vaccination were excluded to be consistent with Centers for Disease Control and Prevention (CDC) guidelines.<sup>3</sup> Here we compare rates of adverse events following vaccination for nursing home residents with the following: (1) no prior infection; (2) symptomatic infection before vaccination, excluding within 20 days of vaccination; and (3) asymptomatic infection before vaccination, excluding within 20 days of vaccination.

## Methods

Our study population included 20,918 nursing home residents of 284 facilities within Genesis Healthcare, a large nursing home provider spanning 24 US states. De-identified electronic health record (EHR) data from January 2020 to present were collected from the study population containing daily residents' dispositions, vaccinations, diagnoses, SARS-CoV-2 testing records, nursing documentation on symptoms, and other clinical data. Genesis coordinated with the CDC's Pharmacy Partnership of Long-term Care Program to provide each of their nursing homes with 3 COVID-19 vaccine clinics carried out over a 3-month period to vaccinate residents and staff. The vaccine received (eg, Moderna or Pfizer-BioNTech) varied by state. The Brown University Institutional Review Board approved this study.

### Study Design

The study residents received their first dose of mRNA vaccine between December 18, 2020, and February 14, 2021. Consistent with CDC guidelines,<sup>3</sup> we excluded residents with a positive SARS-CoV-2 diagnostic test within 20 days before vaccination, as well as those treated with SARS-CoV-2 monoclonal antibodies for 90 days before vaccination.

### Exposure Groups

The 3 groups compared included those who, at time of vaccination, had (1) no previous diagnosis of SARS-CoV-2, (2) previous infection with symptoms (more than 20 days before vaccination), and (3) previous infection without symptoms (more than 20 days before vaccination). For residents with prior SARS-CoV-2 infection, we obtained symptom data from change in condition notes that nurses complete when residents present with any new symptoms. We classified residents as having asymptomatic or symptomatic infection based on whether they had any SARS-CoV-2–related symptoms from 5 days before up to 14 days after a positive test or diagnosis.

### Outcomes

Serious outcomes, such as mortality, were monitored for 7 days post-vaccination. If a resident died in the hospital shortly after transfer, or when they were expected to return to a Genesis facility, Genesis was notified of the death, and thus the death was captured in this analysis. Other adverse events that could manifest somewhat longer post-vaccination were monitored for 15 days using International Classification of Diseases, 10<sup>th</sup> Revision, Clinical Modification (ICD-10-CM) codes included in residents' EHR problem lists. Those events, listed in [Table 1](#), were classified by the Brighton Collaboration<sup>4</sup> using ICD-10-CM codes for diagnoses and exclusions available from the CDC's Vaccine Safety Datalink.<sup>5</sup> For most events, prevalent cases were excluded to ensure capturing only incident cases.

### Physician Chart Reviews

Physician chart review was conducted on all flagged cases of adverse events to confirm the diagnoses. To do this, the de-identified EHR record was shared back with Genesis for secure linkage to the original medical record number, so that the physician could review the resident's chart directly in the nursing home's EHR. The purposes of the chart reviews were to identify whether events were incident (new onset), recent prevalent conditions (within the past 30 days), or incorrectly coded diagnoses.

### Statistical Analysis

We used SAS version 9.4 software (SAS Institute, Inc., Cary, NC) for data management and to compute frequencies and  $\chi^2$  tests to assess statistical differences in baseline characteristics of residents. Adverse events identified, and their rates and 95% Wilson's confidence intervals (CIs) were calculated per 100,000 residents.<sup>6</sup> We used STATA version 16 software (StataCorp, College Station, TX) for the adjusted analysis, using multilevel logistic regression that adjusted for clustering (variability) across nursing homes. To balance the probability of prior SARS-CoV-2 infection more than 20 days before vaccination, we used inverse probability weighting. This was incorporated into the logistic regression model to adjust for the baseline probability of prior SARS-CoV-2 infection. A sandwich estimator was used to account for correlation within facilities.<sup>7,8</sup> Variables in the propensity score model included age, sex, race/ethnicity, diabetes, chronic obstructive pulmonary disease, chronic kidney disease, congestive heart failure,

**Table 1**  
Adverse Events Monitored

Acute disseminated encephalomyelitis
Acute myocardial infarction
Acute respiratory distress syndrome
Anaphylaxis
Appendicitis
Bell's palsy
Convulsions/Seizures
Disseminated intravascular coagulation
Encephalitis/Myelitis/Encephalomyelitis/Encephalopathy
Guillain-Barré syndrome
Thrombotic thrombocytopenic purpura
Immune thrombocytopenia
Multisystem inflammatory syndrome in adults
Myocarditis/pericarditis
Narcolepsy and cataplexy
Stroke, hemorrhagic
Stroke, ischemic
Transverse myelitis
Venous thromboembolism
Pulmonary embolism
Death

coronary artery disease, dementia, hypertension, activities of daily living score, mortality risk, and cognitive function scale score. To adjust for multiplicity, we used a false discovery rate procedure.<sup>9</sup>

#### Sensitivity Analysis

Although the focus of this study was to determine whether adverse event rates after vaccination differed between those with and without previous SARS-CoV-2 infection, we also compared the incidence of adverse events among the vaccinated and unvaccinated groups. Because our population was mostly vaccinated by mid-February 2021, the best unvaccinated comparator group was the “yet-to-be vaccinated,” unvaccinated population from our previous study.<sup>2</sup> Details on the unvaccinated group are published elsewhere.<sup>2</sup> To obtain a large enough sample of residents with previous infection, with and without symptoms, we included all residents who received the first dose from December 18, 2020, through February 14, 2021.

#### Results

We included 20,918 residents across 284 nursing homes who received their first mRNA vaccine dose between December 18, 2020, and February 14, 2021. Statistically significant differences existed between those without ( $n = 13,163$ ) and with previous SARS-CoV-2 infection [symptomatic ( $n = 5617$ ) and asymptomatic ( $n = 2138$ )] for all baseline characteristics assessed (Table 2). For example, higher proportions of residents with prior infection, symptomatic or asymptomatic, were long-stay (lived in the nursing home 100 or more days) than those with no prior infection. Male residents were more likely to have had no previous SARS-CoV-2 infection than female residents. Similarly, residents younger than 65 years were more likely to have had no previous SARS-CoV-2 infection than were older residents; and cognitively intact residents were also more likely to have had no previous infection compared with cognitively impaired residents. Those with previous symptomatic infection were more likely to have comorbidities than the other 2 groups.

#### Adverse Events

Chart reviews were conducted to verify events identified using ICD-10-CM codes. One case occurred within 15 days after vaccination among those who had no previous SARS-CoV-2 infection (7.6 per 100,000; 95% CI: 1.3–43.0) that did not occur among those with a

previous SARS-CoV-2 infection for the following events: acute myocardial infarction, Bell's palsy, hemorrhagic stroke, ischemic stroke, and pulmonary embolism. (Table 3) In addition, 3 cases of seizures occurred among those with no previous infection, whereas none occurred among those with previous infection. Four cases of venous thromboembolism occurred among those with no previous infection (30.4 per 100,000; 95% CI: 11.8–78.1) and 1 case occurred among those with a previous asymptomatic infection (46.8 per 100,000; 95% CI: 8.3–264.5).

Compared with residents with no previous SARS-CoV-2 infection, we observed statistically significantly lower adjusted mortality rates among residents with previous symptomatic infection (risk ratio (RR): 0.61, 95% CI: 0.49–0.76) and residents with previous asymptomatic infection (RR: 0.51, 95% CI: 0.35–0.73).

In sensitivity analyses comparing rates of adverse events among residents vaccinated with no previous SARS-CoV-2 infection with the unvaccinated from our previous study,<sup>2</sup> we found no statistically significant difference in rates for venous thromboembolism (RR: 0.46, 95% CI 0.05–4.02) or for pulmonary embolism (RR: 0.42, 95% CI: 0.04–4.58). After adjustment for multiple testing, we found that none of these *P* values were statistically significant: acute myocardial infarction (0.51), Bell's palsy (0.51), hemorrhagic stroke (0.51), ischemic stroke (0.42), seizures (0.42), pulmonary embolism (0.53), and venous thromboembolism (0.53).

#### Discussion

Although reactogenicity increases with preexisting immunity,<sup>10</sup> we did not observe higher rates of adverse events among nursing home residents with versus without prior natural infection. In fact, our study suggests that SARS-CoV-2 infection, regardless of whether it was symptomatic or asymptomatic, did not increase the risk of adverse events following COVID-19 vaccination. Although we identified some adverse events following vaccination among those with no previous SARS-CoV-2 infection that did not occur among the unvaccinated, no differences in rates were statistically significant after adjustment for multiplicity using a false discovery rate procedure.<sup>9</sup>

One reason for the lower mortality among those with previous SARS-CoV-2 infection, symptomatic or asymptomatic, compared with those with no previous infection could be selective survival, or immortal time bias.<sup>11</sup> In other words, those who survived SARS-CoV-2 infection and were healthy enough to get vaccinated months later may have been less likely to die than those coming into the nursing home with no previous infection, even after adjustments for comorbidities. Because of the disparity in long-stay (ie, those with previous infection were more likely to be long-stay than those with no previous infection), we ran the mortality analyses excluding short-stay residents, and mortality remained statistically significantly lower among those with previous SARS-CoV-2 infection, symptomatic or asymptomatic, than those with no previous infection (results not presented). Moreover, younger (<65 years) residents were more likely to have had no previous infection, whereas older (aged 85 years and older) residents were more likely to have had a previous asymptomatic infection. Thus, those older adults with previous asymptomatic infection may have been “healthier” than the younger adults who entered the nursing home without a previous infection.

Our study had a few key limitations. First, there were significant differences in baseline characteristics between those with no previous SARS-CoV-2 infection and those with previous symptomatic or asymptomatic infection. We used inverse probability weighting to adjust for the baseline probability of previous SARS-CoV-2 infection based on observed values. However, there are still indications that there may be other unobserved factors that may influence the lack of significant evidence for differences in adverse events rates among

**Table 2**  
Demographic and Clinical Characteristics of Vaccinated Nursing Home Residents by Previous SARS-CoV-2 Status

			No Previous SARS-CoV-2 Diagnosis or Positive Test		Previous SARS-CoV-2 Diagnosis or Positive Test With Symptoms		Previous SARS-CoV-2 Diagnosis or Positive Test Without Symptoms		P-value*
	n	(%)	n (%)		n (%)		n (%)		
Long-stay (> 100 days)	14,681	(73.2)	8072	(63.8)	5107	(94.8)	1502	(74.5)	<.01
Short-stay (≤ 100 days)	5380	(26.8)	4587	(36.2)	278	(5.2)	515	(25.5)	
Sex									<.01
Male	7973	(38.1)	5156	(39.2)	2038	(36.3)	779	(36.5)	
Female	12,938	(61.9)	8001	(60.8)	3579	(63.7)	1358	(63.5)	
Age group, y									.01
<65	3874	(18.5)	2494	(19.0)	1027	(18.3)	353	(16.5)	
65–74	4891	(23.4)	3037	(23.1)	1379	(24.6)	475	(22.2)	
75–84	5918	(28.3)	3719	(28.2)	1602	(28.5)	597	(27.9)	
≥ 85	6235	(29.8)	3913	(29.7)	1609	(28.6)	713	(33.4)	
Race/Ethnicity									
Black	2551	(12.2)	1533	(11.7)	764	(13.6)	254	(11.9)	<.01
Hispanic	980	(4.7)	566	(4.3)	298	(5.3)	116	(5.4)	<.01
Comorbidities									
COPD	5614	(27.1)	3441	(26.5)	1660	(29.7)	513	(24.3)	<.01
Dementia	9232	(44.6)	5336	(41.1)	2870	(51.3)	1026	(48.5)	<.01
Coronary artery disease	5385	(26.0)	3366	(25.9)	1532	(27.4)	487	(23.0)	<.01
Diabetes	8124	(38.9)	5054	(38.5)	2313	(41.2)	757	(35.4)	<.01
Congestive heart failure	4944	(23.9)	3105	(23.9)	1426	(25.5)	413	(19.5)	<.01
Chronic kidney disease	5714	(27.6)	3638	(28.0)	1572	(28.1)	504	(23.8)	<.01
Hypertension	16,394	(79.3)	10175	(78.4)	4577	(81.8)	1642	(77.7)	<.01
Cognitive function scale									<.01
Cognitively intact	6009	(29.0)	4152	(31.9)	1301	(23.2)	556	(26.3)	
Mildly impaired	4961	(23.9)	3094	(23.7)	1352	(24.2)	515	(24.4)	
Moderately impaired	6811	(32.9)	4034	(31.0)	2035	(36.4)	742	(35.2)	
Severely impaired	2949	(14.2)	1746	(13.4)	905	(16.2)	298	(14.1)	
ADL score, mean (SD)	19.2	(5.5)	19.0	(5.5)	19.7	(5.5)	18.6	(5.8)	
ADL dependency quartile									<.01
0–17	5521	(26.4)	3567	(27.2)	1330	(23.7)	624	(29.3)	
18–20	5935	(26.8)	3769	(28.7)	1273	(22.7)	551	(25.8)	
21–22	4457	(21.4)	2692	(20.5)	1301	(23.1)	464	(21.7)	
23–28	5306	(25.4)	3099	(23.6)	1711	(30.5)	496	(23.2)	

ADL, activities of daily living; COPD, chronic obstructive pulmonary disease.

Note: Includes all residents who received at least 1 dose of vaccine.

\*Indicates  $\chi^2$  test P value.

these populations. Second, to conduct timely analyses, adverse events were included only if they were diagnosed by the medical provider with a supporting ICD-10-CM code. Third, the relatively small sample size to assess rare adverse events resulted in an inability to generate

precise estimates. However, the extremely low number of suspected adverse events was reassuring and an important finding of the study.

This study contributes new evidence that older, frail nursing home residents with previous SARS-CoV-2 infection do not seem to be at

**Table 3**  
Adverse Events Diagnosed Among Vaccinated Residents by Previous SARS-CoV-2 Status

	No Previous SARS-CoV-2 Diagnosis or Positive Test n = 13,163		Previous SARS-CoV-2 Diagnosis or Positive Test With Symptoms n = 5617				Previous SARS-CoV-2 Diagnosis or Positive Test Without Symptoms n = 2138		
	n	Unadjusted Rate Per 100,000*	n	Unadjusted Rate Per 100,000*	Previous Symptomatic Vs No Previous	Previous Symptomatic Vs Asymptomatic	n	Unadjusted Rate Per 100,000*	Previous Asymptomatic Vs No Previous
					Adjusted Risk Ratio	Adjusted Risk Ratio			
<b>15-day event rates</b>									
Acute myocardial infarction	1	7.6 (1.3–43.0)	0	—	—	—	0	—	—
Bell's palsy	1	7.6 (1.3–43.0)	0	—	—	—	0	—	—
Convulsions/Seizures	3	22.8 (7.8–67.0)	0	—	—	—	0	—	—
Stroke, hemorrhagic	1	7.6 (1.3–43.0)	0	—	—	—	0	—	—
Stroke, ischemic	1	7.6 (1.3–43.0)	0	—	—	—	0	—	—
Venous thromboembolism	4	30.4 (11.8–78.1)	0	—	—	—	1	46.8 (8.3–264.5)	1.77 (0.20–15.78)
Pulmonary embolism	1	7.6 (1.3–43.0)	0	—	—	—	0	—	—
<b>7-day event rates</b>									
Death	93	706.5 (577.1–864.7)	31	551.9 (389.1–782.3)	0.61 (0.49–0.76)	1.20 (0.81–1.77)	12	561.3 (321.4–978.5)	0.51 (0.35–0.73)

Adjusted risk ratios: Inverse probability weighting was used to adjust the probability of previous SARS-CoV-2 diagnosis by age, gender, race/ethnicity, diabetes, chronic obstructive pulmonary disease, renal disease, hypertension, congestive heart failure, coronary heart disease, dementia, cognitive function, mortality risk and physical function. Note: Residents with a positive SARS-CoV-2 test within 20 days of vaccination (because they should not have been vaccinated), or who were on monoclonal antibodies within 90 days of vaccination were excluded. Previous SARS-CoV-2 diagnosis or positive test were 21 or more days before vaccination. Symptoms presented within the 5 days before or up to 14 days after the previous SARS-CoV-2 diagnosis or positive test.

\*Wilson's 95% CIs.

higher risk of adverse events following the first dose of mRNA vaccine than their vaccinated counterparts with no previous infection, nor do they seem to be at a higher risk of adverse events compared with their unvaccinated counterparts. In addition, it is important to stress the finding in our previous study that mortality rates after vaccination were not higher than mortality rates among the unvaccinated.<sup>2</sup> This research supports previous reports from the original randomized trials of these vaccines,<sup>12,13</sup> although nursing home residents were not included in those trials. Moreover, the mRNA-based vaccines have demonstrated safety, and offer the prospect of being life-saving for nursing home residents who have borne a disproportionate share of morbidity and mortality from COVID-19.<sup>14</sup>

## Conclusions and Implications

Our study suggests that frail, nursing home residents with a previous SARS-CoV-2 infection, whether symptomatic or not, were not at higher risk of adverse events following vaccination, compared with those who had no previous infection. This study further stresses the importance of having the infrastructure to support near real-time monitoring of adverse events, safety, and efficacy of novel vaccines in this vulnerable population.

## References

1. Krammer FS, Srivastava K, Alshammary H, et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. *N Engl J Med* 2021;384:1372–1374.
2. Bardenheier BH, Gravenstein S, Blackman C, et al. Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents. *Vaccine* 2021;39:3844–3851.
3. Centers for Disease Control and Prevention. Frequently Asked Questions about COVID-19 vaccination. Published 2021. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/faq.html>. Accessed July 15, 2021.
4. Brighton Collaboration. Priority list of adverse events of special interest: COVID-19. The Task Force for Global Health. Published 2020. Available at: [https://brightoncollaboration.us/wp-content/uploads/2021/01/SO2\\_D2.1.2\\_V1.2\\_COVID-19\\_AESI-update-23Dec2020-review\\_final.pdf](https://brightoncollaboration.us/wp-content/uploads/2021/01/SO2_D2.1.2_V1.2_COVID-19_AESI-update-23Dec2020-review_final.pdf). Accessed March 11, 2021.
5. Vaccine Safety Datalink. Rapid Cycle Analysis (RCA) to monitor the safety of COVID-19 vaccines in near real-time within the Vaccine Safety Datalink. Centers for Disease Control and Prevention. Published 2021. Available at: [https://www.cdc.gov/vaccinesafety/pdf/VSD-1342-COVID19-RCA-Protocol\\_FinalV1.1\\_508.pdf](https://www.cdc.gov/vaccinesafety/pdf/VSD-1342-COVID19-RCA-Protocol_FinalV1.1_508.pdf). Accessed June 1, 2021.
6. Brown LD, Cai TT, DasGupta A, et al. Interval estimation for a binomial proportion - Comment - Rejoinder. *Stat Sci* 2001;16:101–133.
7. Royall RM. Model robust confidence-intervals using maximum-likelihood estimators. *Int Stat Rev* 1986;54:221–226.
8. Cattaneo MD. Efficient semiparametric estimation of multi-valued treatment effects under ignorability. *J Econometrics* 2010;155:138–154.
9. Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. *J R Stat Soc B* 1995;57:289–300.
10. Ossato A, Tessari R, Trabucchi C, et al. Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021. *Eur J Hosp Pharm*; 2021 July 27 [Epub ahead of print].
11. Hernan MA, Sauer BC, Hernandez-Diaz S, et al. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. *J Clin Epidemiol* 2016;79:70–75.
12. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med* 2020;383:2603–2615.
13. Chen M, Yuan Y, Zhou Y, et al. Safety of SARS-CoV-2 vaccines: A systematic review and meta-analysis of randomized controlled trials. *Infect Dis Poverty* 2021;10:94.
14. Grabowski DC, Mor V. Nursing home care in crisis in the wake of COVID-19. *JAMA* 2020;324:23–24.